<DOC>
	<DOCNO>NCT00522743</DOCNO>
	<brief_summary>A 2-arms randomized open prospective intervention study determine Growth metabolic response growth hormone gonadotropin-releasing hormone agonist treatment versus growth hormone alone boys born SGA . All subject treat NorditropinSimplex dosage 100mcg/kg/d . At onset puberty , subject randomize either combine treatment GH GnRHa GH alone .</brief_summary>
	<brief_title>Growth Metabolic Response GH GnRHa Treatment Versus GH Alone Boys Born SGA .</brief_title>
	<detailed_description>A 2-arms randomized open prospective intervention study include 20 boy , order determine effect growth hormone ( GH ) gonadotropin-releasing hormone agonist treatment versus growth hormone ( GnRHa ) alone growth metabolic response . Objectives : The primary objective investigate effect delay pubertal process pubertal suppression growth final height boy bear SGA treat GH . The secondary objective determine metabolic effect combine therapy GH plus gonadotropin agonist GH alone dietary intake , serum leptin , ghrelin , IGF-1 , lipid lipoprotein concentration prior treatment , ass quality life two group . Study population : 20 prepubertal boy . Inclusion Criteria : 1 . Ages 10-13 2 . IUGR 3 . Height least 2 standard deviation mean height chronological age sex accord 2000 standard Centers Disease Control Prevention ( CDC ) . 4. prepubertal ( Tanner stage 1 ) commencement trail . 5 . Peak GH 10ng/ml least one provocative test GH secretion . 6 . Signed informed consent form . Exclusion criterion : 1 . Growth retardation associate malignancy , severe chronic disease , genetic syndrome endocrine disorder . 2 . Diabetes . 3 . Treatment medical product may interfere GH effect . Trail design : A prospective , randomize control study assess impact two year combine treatment GH GnRHa height boy severe growth failure due SGA height &gt; 2.25 SDS , compare GH alone . All subject treat NorditropinSimplex dosage 100mcg/kg/d . At onset puberty ( testicular volume great 4 ml consecutive examination ) subject randomize either combine treatment GH GnRHa GH alone . Methods : 1 . Urine test hold every three month . 2 . X-ray photograph bone age determination take baseline every year . 3 . Blood take baseline every year order evaluate follow parameter : Lipid lipoprotein concentration , ghrelin , leptin , glucose , insulin HbA1c . 4 . Blood take randomization visit three month order evaluate follow parameter : LH , FSH Testosterone 5 . Blood take baseline every half year evaluate level IGF-1 . 6 . For evaluation growth hormone response , additional blood test preform one month three month treatment growth hormone . 7 . On every blood urine take , proteomic analysis hold . 8 . Before treatment growth hormone , one year treatment end study quality life questionnaire , appetite questionnaire Psychological questionnaires fill . The safety growth hormone treatment assess : 1 . Monitoring adverse event . 2 . Measurement HbA1c . 3 . Measurement hematology , serum biochemistry urinalysis laboratory variable . 4 . Measurement fast glucose insulin concentration . 5 . IGF-1 6 . Physical examination measurement vital sign height body weight . 7 . Measurement bone age .</detailed_description>
	<mesh_term>Hormones</mesh_term>
	<criteria>1 . Boys 2 . IUGR 3 . Ages 1013 4. height list 2.0 standard deviation mean height chronological age sex accord 2000 standard Centers Disease Control Prevention ( CDC ) 5 . Prepubertal ( tanner stage 1 ) commencement trail 6 . Peak GH 10ng/ml least one provocative test GH secretion 7.Signed informed consent 1 . Growth retardation associate malignancy , severe chronic disease , genetic syndrome endocrine disorder 2 . Diabetes 3 . Treatment medical product may interfere GH effect</criteria>
	<gender>Male</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>13 Years</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>SGA</keyword>
	<keyword>GH</keyword>
	<keyword>GnRHa</keyword>
	<keyword>IGF-1</keyword>
</DOC>